Recent developments in health include EU approval of Novo's Wegovy for obesity-related heart conditions, the US FDA's nod for ...

Few medications have become as popular and culturally relevant as Ozempic has, but how exactly do it and similar drugs affect ...

Novo Nordisk, tje manufacturer behind Ozempic and Wegovy has another weight loss medication in the works — but according to ...

Recent health developments include the EU backing Novo Nordisk's Wegovy for obesity-related heart conditions, FDA approvals ...

We’re firmly in the “buyer beware” era of obesity drugs. And unfortunately, it seems like we’re going to be stuck here for a ...

Discounts of as much as half on the $1,000-plus-a-month injectables are meant to induce insurers to offer coverage to workers ...

A next-generation obesity drug candidate from Novo Nordisk produced modest weight loss, along with a higher rate of some ...

Novo Nordisk announced positive Phase 2a trial results for monlunabant, showing significant weight loss with a 10 mg dose.

Novo Nordisk's U.S.-listed shares lost ground Friday after a study of the pharmaceutical firm’s latest obesity treatment ...

Ozempic maker Novo Nordisk (NVO) announced mixed results today for a phase 2 trial of an experimental weight loss pill that ...

In this morning’s readout from Novo's phase 2 trial of monlunabant in 243 people with obesity and metabolic syndrome, it ...